Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

NCT00992589 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux

Interventions

DRUG: Rabeprazole sodium 5 mg
DRUG: Rabeprazole sodium 10 mg
DRUG: Placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]